Role of the Inhibitory Quotient in HIV Therapy
- 1 November 2005
- journal article
- review article
- Published by SAGE Publications in Antiviral Therapy
- Vol. 10 (8) , 879-892
- https://doi.org/10.1177/135965350501000802
Abstract
A systemic review is presented of all studies that have evaluated the inhibitory quotient (IQ). The IQ is defined as the ratio between (trough) drug concentration and level of drug resistance of the HIV isolate. From the studies presented, it can be concluded that for protease inhibitors (PIs) and efavirenz, the phenotypic IQ is associated with virological response. The genotypic IQ (GIQ) for PIs was also demonstrated to be associated with virological response. An intrinsic limitation of the GIQ is that it is only applicable for PIs, of which resistance is based on the cumulative effect of mutations. As the IQ can be modified by adjustment of the drug dosage, it may be of clinical value. Its application in patient care should therefore be further investigated.Keywords
This publication has 76 references indexed in Scilit:
- Prevalence of Antiretroviral Drug Resistance Mutations in Chronically HIV-Infected, Treatment-Naive Patients: Implications for Routine Resistance Screening before Initiation of Antiretroviral TherapyClinical Infectious Diseases, 2005
- Clinical Pharmacokinetics and Summary of Efficacy and Tolerability of AtazanavirClinical Pharmacokinetics, 2005
- Primary Care Guidelines for the Management of Persons Infected with Human Immunodeficiency Virus: Recommendations of the HIV Medicine Association of the Infectious Diseases Society of AmericaClinical Infectious Diseases, 2004
- Estimation of Serum-Free 50-Percent Inhibitory Concentrations for Human Immunodeficiency Virus Protease Inhibitors Lopinavir and RitonavirAntimicrobial Agents and Chemotherapy, 2004
- Impact of Drug Levels and Baseline Genotype and Phenotype on the Virologic Response to Amprenavir/Ritonavir-Based Salvage RegimensAIDS Patient Care and STDs, 2004
- Antiviral dynamics and sex differences of zidovudine and lamivudine triphosphate concentrations in HIV-infected individualsAIDS, 2003
- Therapeutic Drug MonitoringDrugs, 2003
- Efficacy of a twice-daily antiretroviral regimen containing 100 mg ritonavir/400 mg indinavir in HIV-infected patientsAIDS, 2003
- Amprenavir Inhibitory Quotient and Virological Response in Human Immunodeficiency Virus-Infected Patients on an Amprenavir-Containing Salvage Regimen without or with RitonavirAntimicrobial Agents and Chemotherapy, 2002
- Changing patterns of mortality across Europe in patients infected with HIV-1The Lancet, 1998